Future Treatment of Hypertension: Shifting the Focus from Blood Pressure Lowering to Arterial Stiffness Modulation?

Current Hypertension Reports

Volumn 17, Issue 8, 2015, Pages

  Fok, Henry ^a   Cruickshank, J Kennedy ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antihypertensive drugs; Arterial stiffness; Isolated systolic hypertension; Pulse pressure; Pulse wave velocity

Indexed keywords

ANTIHYPERTENSIVE AGENT;

AORTA PRESSURE; ARTERIAL STIFFNESS; BLOOD PRESSURE REGULATION; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HEMODYNAMICS; HUMAN; ISOLATED SYSTOLIC HYPERTENSION; MORTALITY; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR SYSTEM; PREDICTION; PREDICTIVE VALUE; PROGNOSIS; PULSE PRESSURE; PULSE WAVE; REVIEW; RISK MANAGEMENT; SYSTOLIC HYPERTENSION; VASCULAR RESISTANCE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HYPERTENSION; PHYSIOLOGY; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HEMODYNAMICS; HUMANS; HYPERTENSION; RISK FACTORS; VASCULAR STIFFNESS;

EID: 84937550314     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-015-0569-6     Document Type: Review

References (142)

1. A global brief on hypertension: Silent Killer, global public health crisis. 2013.
2. Go AS et al. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28–e292.
3. Mancia G et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of hypertension (ESH) and of the european society of cardiology (ESC). Eur Heart J. 2013;34(28):2159–219.
4. Benetos A et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension. 1997;30(6):1410–5.
5. Madhavan S et al. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension. 1994;23(3):395–401.
6. Darne B et al. Pulsatile versus steady component of blood pressure: a cross-sectional analysis and a prospective analysis on cardiovascular mortality. Hypertension. 1989;13(4):392–400.
7. Fang J et al. Measures of blood pressure and myocardial infarction in treated hypertensive patients. J Hypertens. 1995;13(4):413–9.
8. Benetos A et al. A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with a higher cardiovascular mortality in men. J Am Coll Cardiol. 2000;35(3):673–80.
9. Blacher J et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med. 2000;160(8):1085–9.
10. Glynn RJ et al. Pulse pressure and mortality in older people. Arch Intern Med. 2000;160(18):2765–72.
11. Domanski MJ et al. Isolated systolic hypertension: prognostic information provided by pulse pressure. Hypertension. 1999;34(3):375–80.
12. Lee ML, Rosner BA, Weiss ST. Relationship of blood pressure to cardiovascular death: the effects of pulse pressure in the elderly. Ann Epidemiol. 1999;9(2):101–7.
13. Staessen JA et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355(9207):865–72.
14. Gasowski J et al. Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups. J Hypertens. 2002;20(1):145–51.
15. Franklin SS et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation. 1999;100(4):354–60.
16. Palmieri V et al. Association of pulse pressure with cardiovascular outcome is independent of left ventricular hypertrophy and systolic dysfunction: the Strong Heart Study. Am J Hypertens. 2006;19(6):601–7.
17. Franklin SS et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on national health and nutrition examination survey (NHANES) III. Hypertension. 2001;37(3):869–74.
18. Sever PS et al. Blood pressure reduction is not the only determinant of outcome. Circulation. 2006;113(23):2754–72. discussion 2773–4.
19. Poulter NR et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the anglo-scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA). Lancet. 2005;366(9489):907–13.
20. Dahlof B et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003.
21. Dawes M et al. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol. 1999;48(3):460–3.
22. van der Zander K et al. Nitric oxide and potassium channels are involved in brain natriuretic peptide induced vasodilatation in man. J Hypertens. 2002;20(3):493–9.
23. Collier JG, Lorge RE, Robinson BF. Comparison of effects of tolmesoxide (RX71107), diazoxide, hydrallazine, prazosin, glyceryl trinitrate and sodium nitroprusside on forearm arteries and dorsal hand veins of man. Br J Clin Pharmacol. 1978;5(1):35–44.
24. Benjamin N et al. Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol. 1989;412:543–55.
25. Robinson BF, Dobbs RJ, Kelsey CR. Effects of nifedipine on resistance vessels, arteries and veins in man. Br J Clin Pharmacol. 1980;10(5):433–8.
26. Nichols WW, O’Rourke MF, McDonald’s blood flow in arteries: theoretical, experimental and clinical applications. 2005, 5th Edition, Hodder Arnold.
27. Black HR et al. The first report of the systolic and pulse pressure (SYPP) working group. J Hypertens Suppl. 1999;17(5):S3–14.
28. Izzo Jr JL, Levy D, Black HR. Clinical advisory statement. Importance of systolic blood pressure in older americans. Hypertension. 2000;35(5):1021–4.
29. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens. 2002;20(8):1461–4.
30. Bejan-Angoulvant T et al. Treatment of hypertension in patients 80 years and older: the lower the better? a meta-analysis of randomized controlled trials. J Hypertens. 2010;28(7):1366–72.
31. Wald DS et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290–300.
32. Boutitie F et al. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data. Ann Intern Med. 2002;136(6):438–48.
33. Bramwell JCH. Velocity of transmission of the pulse-wave. Lancet. 1922;199(5149):891–2.
34. Wiggers CJ. Physical and physiological aspects of arteriosclerosis and hypertension*. Ann Intern Med. 1932;6(1):12–30.
35. Wang JJ et al. Time-domain representation of ventricular-arterial coupling as a windkessel and wave system. Am J Physiol Heart Circ Physiol. 2003;284(4):H1358–68.
36. Davies JE et al. Excess pressure integral predicts cardiovascular events independent of other risk factors in the conduit artery functional evaluation substudy of anglo-scandinavian cardiac outcomes trial. Hypertension. 2014;64(1):60–8.
37. Cecelja M et al. Progression of central pulse pressure over 1 decade of aging and its reversal by nitroglycerin a twin study. J Am Coll Cardiol. 2012;59(5):475–83.
38. Scuteri A et al. Longitudinal perspective on the conundrum of central arterial stiffness, blood pressure, and aging. Hypertension. 2014;64(6):1219–27.
39. Ben-Shlomo Y et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol. 2014;63(7):636–46.
40. McEniery CM et al. Aortic calcification is associated with aortic stiffness and isolated systolic hypertension in healthy individuals. Hypertension. 2009;53(3):524–31.
41. Cruickshank JK et al. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation. 2002;106(16):2085–90.
42. Ronnback M et al. Altered age-related blood pressure pattern in type 1 diabetes. Circulation. 2004;110(9):1076–82.
43. Mahmud A, Feely J. Effect of smoking on arterial stiffness and pulse pressure amplification. Hypertension. 2003;41(1):183–7.
44. Van Bortel LM et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012;30(3):445–8.
45. van der Heijden-Spek JJ et al. Effect of age on brachial artery wall properties differs from the aorta and is gender dependent: a population study. Hypertension. 2000;35(2):637–42.
46. Cameron JD et al. The aging of elastic and muscular arteries: a comparison of diabetic and nondiabetic subjects. Diabetes Care. 2003;26(7):2133–8.
47. Vlachopoulos C et al. Prediction of cardiovascular events and all-cause mortality with brachial-ankle elasticity index: a systematic review and meta-analysis. Hypertension. 2012;60(2):556–62.
48. Cecelja M et al. Arterial stiffening relates to arterial calcification but not to noncalcified atheroma in women. A Twin Study J Am Coll Cardiol. 2011;57(13):1480–6.
49. Ge D et al. Heritability of arterial stiffness in black and white American youth and young adults. Am J Hypertens. 2007;20(10):1065–72.
50. O’Donnell CJ et al. Evidence for heritability of abdominal aortic calcific deposits in the Framingham Heart Study. Circulation. 2002;106(3):337–41.
51. Gardiner HM et al. Twin-twin transfusion syndrome: the influence of intrauterine laser photocoagulation on arterial distensibility in childhood. Circulation. 2003;107(14):1906–11.
52. Gardiner HM et al. Vascular programming in twins: the effects of chorionicity and fetal therapy for twin-to-twin transfusion syndrome. J Dev Orig Health Dis. 2012;3(3):182–9.
53. Gardiner HM et al. Cardiac function in 10-year-old twins following different fetal therapies for twin-twin transfusion syndrome. Ultrasound Obstet Gynecol. 2014;43(6):652–7.
54. Pan M et al. Outcome of monochorionic twin pregnancies with abnormal umbilical artery Doppler between 16 and 20 weeks of gestation. J Matern Fetal Neonatal Med. 2012;25(3):277–80.
55. Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review. Hypertension. 2009;54(6):1328–36.
56. Akhtar R et al. Characterizing the elastic properties of tissues. Mater Today (Kidlington). 2011;14(3):96–105.
57. Akhtar R et al. Localized micro- and nano-scale remodelling in the diabetic aorta. Acta Biomater. 2014;10(11):4843–51.
58. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25(5):932–43.
59. Safar, ME, O’Rourke MF. Arterial stiffness in hypertension. 1st edition Handbook of Hypertension, eds. B.W.H.R. J.L. Vol. 23. 2006: Elsevier. 598.
60. van der Loo B et al. Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med. 2000;192(12):1731–44.
61. Mollnau H et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res. 2002;90(4):E58–65.
62. Usui M et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation. 2000;101(3):305–10.
63. Kato H et al. Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J Hypertens. 1991;9(1):17–22.
64. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest. 1992;90(2):456–61.
65. Blacher J et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens. 1997;10(12 Pt 1):1326–34.
66. Paulis L et al. Direct angiotensin II type 2 receptor stimulation in Nomega-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling. Hypertension. 2012;59(2):485–92. This study showed that chronic angiotensin II type 2 receptor stimulation in rats prevented arterial stiffening and the effects were additive to angiotensin type 1 receptor blockade.
67. Gu JW et al. Sodium induces hypertrophy of cultured myocardial myoblasts and vascular smooth muscle cells. Hypertension. 1998;31(5):1083–7.
68. Draaijer P et al. Vascular distensibility and compliance in salt-sensitive and salt-resistant borderline hypertension. J Hypertens. 1993;11(11):1199–207.
69. Partovian C et al. Effects of a chronic high-salt diet on large artery structure: role of endogenous bradykinin. Am J Physiol. 1998;274(5 Pt 2):H1423–8.
70. Powell JT, Vine N, Crossman M. On the accumulation of D-aspartate in elastin and other proteins of the ageing aorta. Atherosclerosis. 1992;97(2–3):201–8.
71. Virdis A et al. Effect of aliskiren treatment on endothelium-dependent vasodilation and aortic stiffness in essential hypertensive patients. Eur Heart J. 2012;33(12):1530–8.
72. Mitchell GF et al. Changes in aortic stiffness and augmentation index after acute converting enzyme or vasopeptidase inhibition. Hypertension. 2005;46(5):1111–7.
73. Mitchell GF et al. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study. Circulation. 2002;105(25):2955–61.
74. Topouchian J et al. Assessment of the acute arterial effects of converting enzyme inhibition in essential hypertension: a double-blind, comparative and crossover study. J Hum Hypertens. 1998;12(3):181–7.
75. Karalliedde J et al. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension. 2008;51(6):1617–23.
76. Nakamura T et al. Casein hydrolysate containing Val-Pro-Pro and Ile-Pro-Pro improves central blood pressure and arterial stiffness in hypertensive subjects: a randomized, double-blind, placebo-controlled trial. Atherosclerosis. 2011;219(1):298–303.
77. Uzui H et al. Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension. J Cardiovasc Pharmacol Ther. 2014;19(3):304–9.
78. Boutouyrie P et al. Destiffening effect of valsartan and atenolol: influence of heart rate and blood pressure. J Hypertens. 2014;32(1):108–14.
79. Koumaras C et al. Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. J Am Soc Hypertens. 2014;8(2):74–82.
80. Mitchell GF et al. Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy. Hypertension. 2007;49(6):1271–7.
81. Dhaun N et al. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension. 2009;54(1):113–9.
82. Kithas PA, Supiano MA. Spironolactone and hydrochlorothiazide decrease vascular stiffness and blood pressure in geriatric hypertension. J Am Geriatr Soc. 2010;58(7):1327–32.
83. Davies J et al. Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients. Br J Clin Pharmacol. 2005;59(5):520–3.
84. Vlachopoulos C, Hirata K, O’Rourke MF. Effect of sildenafil on arterial stiffness and wave reflection. Vasc Med. 2003;8(4):243–8.
85. Vlachopoulos C et al. Beneficial effect of vardenafil on aortic stiffness and wave reflections. J Clin Pharmacol. 2012;52(8):1215–21.
86. Ichihara A et al. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant. 2002;17(8):1513–7.
87. Kanaki AI et al. Low-dose atorvastatin reduces ambulatory blood pressure in patients with mild hypertension and hypercholesterolaemia: a double-blind, randomized, placebo-controlled study. J Hum Hypertens. 2012;26(10):577–84.
88. Yokoyama H et al. Effects of fluvastatin on the carotid arterial media as assessed by integrated backscatter ultrasound compared with pulse-wave velocity. J Am Coll Cardiol. 2005;46(11):2031–7.
89. Ichihara A et al. Long-term effects of statins on arterial pressure and stiffness of hypertensives. J Hum Hypertens. 2005;19(2):103–9.
90. Orr JS et al. Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults. Hypertension. 2009;54(4):763–8.
91. Ferrier KE et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol. 2002;39(6):1020–5.
92. Liu B et al. Effects of rosuvastatin vs. simvastatin/ezetimibe on arterial wall stiffness in patients with coronary artery disease. Intern Med. 2013;52(24):2715–9.
93. Ng KP et al. Allopurinol is an independent determinant of improved arterial stiffness in chronic kidney disease: a cross-sectional study. PLoS One. 2014;9(3):e91961.
94. Edwards NC et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol. 2009;54(6):505–12.
95. Ait-Oufella H et al. Long-term reduction in aortic stiffness: a 5.3-year follow-up in routine clinical practice. J Hypertens. 2010;28(11):2336–41.
96. Shahin Y, Khan JA, Chetter I. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials. Atherosclerosis. 2012;221(1):18–33.
97. Rizos EC, Agouridis AP, Elisaf MS. The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review. Curr Vasc Pharmacol. 2010;8(5):638–44.
98. Kao MP et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol. 2011;22(7):1382–9.
99. Kass DA et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation. 2001;104(13):1464–70.
100. Zieman SJ et al. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens. 2007;25(3):577–83.
101. Fujimoto N et al. Cardiovascular effects of 1 year of alagebrium and endurance exercise training in healthy older individuals. Circ Heart Fail. 2013;6(6):1155–64.
102. Oudegeest-Sander MH et al. The effect of an advanced glycation end-product crosslink breaker and exercise training on vascular function in older individuals: a randomized factorial design trial. Exp Gerontol. 2013;48(12):1509–17.
103. Hartog JW et al. Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Heart Fail. 2011;13(8):899–908.
104. Lilamand M et al. Flavonoids and arterial stiffness: promising perspectives. Nutr Metab Cardiovasc Dis. 2014;24(7):698–704.
105. Siasos G et al. Favorable effects of concord grape juice on endothelial function and arterial stiffness in healthy smokers. Am J Hypertens. 2014;27(1):38–45.
106. Pase MP, Grima NA, Sarris J. The effects of dietary and nutrient interventions on arterial stiffness: a systematic review. Am J Clin Nutr. 2011;93(2):446–54.
107. Moreau KL et al. Tetrahydrobiopterin improves endothelial function and decreases arterial stiffness in estrogen-deficient postmenopausal women. Am J Physiol Heart Circ Physiol. 2012;302(5):H1211–8.
108. Pierce GL et al. Tetrahydrobiopterin supplementation enhances carotid artery compliance in healthy older men: a pilot study. Am J Hypertens. 2012;25(10):1050–4.
109. Laurent S, Briet M, Boutouyrie P. Arterial stiffness as surrogate end point: needed clinical trials. Hypertension. 2012;60(2):518–22. A well written review article to address the issues surrounding the use of arterial stiffness as a biomarker in clinical trials.
110. Fok H et al. Augmentation pressure is influenced by ventricular contractility/relaxation dynamics: novel mechanism of reduction of pulse pressure by nitrates. Hypertension. 2014;63(5):1050–5. This study introduces the novel concept of LV contractility / dynamics as an important component of the BP lowering properties of organic nitrate (GTN).
111. Yaginuma T et al. Effect of glyceryl trinitrate on peripheral arteries alters left ventricular hydraulic load in man. Cardiovasc Res. 1986;20(2):153–60.
112. Pauca AL, Kon ND, O’Rourke MF. Benefit of glyceryl trinitrate on arterial stiffness is directly due to effects on peripheral arteries. Heart. 2005;91(11):1428–32.
113. Cecelja M et al. Increased wave reflection rather than central arterial stiffness is the main determinant of raised pulse pressure in women and relates to mismatch in arterial dimensions: a twin study. J Am Coll Cardiol. 2009;54(8):695–703.
114. Avolio AP et al. Role of pulse pressure amplification in arterial hypertension: experts’ opinion and review of the data. Hypertension. 2009;54(2):375–83.
115. Vlachopoulos C et al. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J. 2010;31(15):1865–71.
116. Williams B et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the conduit artery function evaluation (CAFE) study. Circulation. 2006;113(9):1213–25.
117. Mackenzie IS et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension. 2009;54(2):409–13.
118. Morgan T et al. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens. 2004;17(2):118–23.
119. Asmar RG et al. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension. 2001;38(4):922–6.
120. Deary AJ et al. Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. Clin Sci (Lond). 2002;103(5):493–9.
121. Simon AC et al. Effect of nitroglycerin on peripheral large arteries in hypertension. Br J Clin Pharmacol. 1982;14(2):241–6.
122. Pauca AL, O’Rourke MF, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension. 2001;38(4):932–7.
123. Fok H et al. Regulation of vascular tone and pulse wave velocity in human muscular conduit arteries: selective effects of nitric oxide donors to dilate muscular arteries relative to resistance vessels. Hypertension. 2012;60(5):1220–5.
124. Jiang XJ et al. Quantification of glyceryl trinitrate effect through analysis of the synthesised ascending aortic pressure waveform. Heart. 2002;88(2):143–8.
125. Kelly RP et al. Vasoactive drugs influence aortic augmentation index independently of pulse-wave velocity in healthy men. Hypertension. 2001;37(6):1429–33.
126. Safar ME et al. Peripheral large arteries and the response to antihypertensive treatment. Hypertension. 1983;5(5 Pt 2):III63–8.
127. Simon AC et al. Action of vasodilating drugs on small and large arteries of hypertensive patients. J Cardiovasc Pharmacol. 1983;5(4):626–31.
128. Simon AC et al. Effects of chronic administration of enalapril and propranolol on the large arteries in essential hypertension. J Cardiovasc Pharmacol. 1985;7(5):856–61.
129. Simon AC et al. Effects of acute and chronic angiotensin-converting enzyme inhibition on large arteries in human hypertension. J Cardiovasc Pharmacol. 1985;7 Suppl 1:S45–51.
130. Maarek BL et al. Comparative effects of propranolol and pindolol on small and large arteries and veins of the forearm circulation in hypertensive man. J Cardiovasc Pharmacol. 1986;8 Suppl 4:S61–6.
131. Van Bortel LM et al. Is it possible to develop drugs that act more selectively on large arteries? J Hypertens. 1999;17(5):701–5.
132. Omar SA et al. Paradoxical normoxia-dependent selective actions of inorganic nitrite in human muscular conduit arteries and related selective actions on central blood pressures. Circulation. 2015;131(4):381–9.
133. Westerhof BE et al. Location of a reflection site is elusive: consequences for the calculation of aortic pulse wave velocity. Hypertension. 2008;52(3):478–83.
134. Davies JE et al. Attenuation of wave reflection by wave entrapment creates a “horizon effect” in the human aorta. Hypertension. 2012;60(3):778–85.
135. Davies JE et al. The arterial reservoir pressure increases with aging and is the major determinant of the aortic augmentation index. Am J Physiol Heart Circ Physiol. 2010;298(2):H580–6.
136. Segers P et al. Assessment of pressure wave reflection: getting the timing right! Physiol Meas. 2007;28(9):1045–56.
137. Hughes AD et al. Limitations of augmentation index in the assessment of wave reflection in normotensive healthy individuals. PLoS One. 2013;8(3):e59371. This study provides further evidence on the limitation of augmentation index as a marker of pressure wave reflection.
138. Fok H et al. Dominance of the forward compression wave in determining pulsatile components of blood pressure: similarities between inotropic stimulation and essential hypertension. Hypertension. 2014;64(5):1116–23.
139. Schultz MG et al. Exercise central (aortic) blood pressure is predominantly driven by forward traveling waves, not wave reflection. Hypertension. 2013;62(1):175–82.
140. Torjesen AA et al. Forward and backward wave morphology and central pressure augmentation in men and women in the Framingham Heart Study. Hypertension. 2014;64(2):259–65.
141. Kapil V et al. Inorganic nitrate supplementation lowers blood pressure in humans: role for nitrite-derived NO. Hypertension. 2010;56(2):274–81.
142. Kapil V et al. Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: a randomized, phase 2, double-blind, placebo-controlled study. Hypertension. 2015;65(2):320–7.